Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (10334)	2/7/2004 11:01:41 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Are two arm studies the norm in Phase II's? My guess is a healthy majority of Phase II's nowadays have a control arm. A lot also have multiple drug arms, with varying doses. Proceeding to a Phase III without first running a controlled Phase II is fairly dangerous - that's what PCYC did - they showed good efficacy when compared with a historical database (case control) but then flamed out in the Phase III. But clearly running a small controlled Phase II is dangerous - chances are you won't show statistical significance and your stock will tank despite your cries that the study wasn't powered to show significance. Peter